Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.5K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

180
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
180
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

812
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
812
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

398
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
398
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

193
Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
193
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

115
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
115

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same author

Somatosensory Amplification and Psychopathological Symptoms: The Mediating Roles of Meteoropathy and Meteosensitivity.

Brain sciences·2026
Same author

Growth Factor Signaling in Solid Organ Transplantation: A Conceptual Framework for Chronic Remodeling and Survival.

International journal of molecular sciences·2026
Same author

Endocannabinoid System-Related Inflammation and Progression of Autosomal Dominant Polycystic Kidney Disease.

International journal of molecular sciences·2026
Same author

EPA guidance on cultural competence training: a critical update and meta-review.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Polish Adaptation and Psychometric Validation of the METEO-Q in Healthy, Cardiac, and Psychiatric Samples.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Aug 9, 2025

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.6K

Complement Activation Products in Patients with Chronic Schizophrenia.

Krzysztof Rudkowski1, Katarzyna Waszczuk1, Ernest Tyburski2

  • 1Department of Psychiatry, Pomeranian Medical University, Broniewskiego 26, 71-460 Szczecin, Poland.

Journal of Clinical Medicine
|February 25, 2023
PubMed
Summary

Elevated complement activation products (CAP) like C3a and C5a are linked to schizophrenia (SCH). These immune markers, particularly C3a and C5b-9, may predict SCH and impact global functioning in patients.

Keywords:
C3aC5aC5b-9PANSScomplement cascadeschizophrenia

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.0K

Related Experiment Videos

Last Updated: Aug 9, 2025

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.6K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.0K

Area of Science:

  • Neuroimmunology
  • Psychiatry
  • Complement System Biology

Background:

  • The immune system, particularly the complement cascade (CC), plays a role in mental health conditions like schizophrenia (SCH).
  • The function of CC components in SCH pathogenesis remains under-investigated.
  • CC is vital for regeneration, including neurogenesis, and immune defense.

Purpose of the Study:

  • To investigate the levels of complement activation products (CAP) in patients with chronic schizophrenia.
  • To explore the association between CAP levels and schizophrenia.
  • To determine if CAP levels correlate with symptom severity or global functioning in schizophrenia.

Main Methods:

  • Compared peripheral blood levels of C3a, C5a, and C5b-9 in 62 chronic schizophrenia patients (disease duration ≥ 10 years) and 25 healthy controls.
  • Controlled for age, sex, BMI, and smoking status.
  • Utilized multivariate logistic regression to identify predictors of SCH.

Main Results:

  • All measured CAP levels (C3a, C5a, C5b-9) were elevated in schizophrenia patients compared to controls.
  • Significant correlations were found between schizophrenia and C3a and C5a levels after controlling for confounders.
  • C3a and C5b-9 were identified as significant predictors of schizophrenia.
  • No significant correlation between CAP levels and symptom severity or general psychopathology was observed.
  • C3a and C5b-9 showed significant links with global functioning in schizophrenia patients.

Conclusions:

  • Increased levels of complement activation products suggest a role for the complement cascade in schizophrenia etiology.
  • These findings highlight immune system dysregulation in schizophrenia.
  • Elevated C3a and C5b-9 may serve as potential biomarkers for schizophrenia and indicators of impaired global functioning.